BMT/Leukemia

With recent increased understanding of disease genetics and development of new therapies, the treatment of Hematologic Malignancies has revolutionized over the past decade with an explosion of new therapeutic options. Now, patients with diseases such as Acute Leukemia, Myelodysplastic Syndrome, and Multiple Myeloma are living longer and better than ever. 

At the University of Arizona Cancer Center, we personalize therapy according to risk and goals of care using a patient-centered approach. We use novel therapies including immunotherapy, targeted therapy, the latest approved drug combinations, and Hematopoietic Cellular Therapy and Transplant (including autologous, allogenic transplant, and CAR-T cells) to attain the best possible disease outcomes.

We value the importance of treating the patient, the whole patient, and providing compassionate care to our patients.

Featured Clinical Trials

A Phase 3 Multicenter Randomized Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t1114Positive Relapsed or Refractory Multiple Myeloma

Phase 1BII Study of Escalating Doses of Pevonedistat Tak924 Formerly MLN4924 Administered in Combination with Standard Induction Chemotherapy Cytarabine and Idarubicin in Newly Diagnosed High Risk Acute Myelogenous Leukemia AML

A Phase IIb Study of Haploidentical Bone Marrow Transplant with PostTransplant Cyclophosphamide andor Bendamustine TEST

Medical Oncology
Medical Oncology
Emmanuel Katsanis, MD
Pediatric Oncology
Medical Oncology
Medical Oncology

Staff

Clinical Research Nursing

Patricia Robles-Medina, BA, MEd, MSRN
520-694-9075

Clinical Research Coordination

Audrey Valencia Johnson
520-694-9084

Research Data Coordination

Richard Kettering
520-626-8218

Regulatory Coordination

Michele Chu
520-626-1183